NAGE vs NAII
Niagen Bioscience, Inc. and Natural Alternatives International Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NAGE | NAII |
|---|---|---|
| Revenue | $129.4M | $129.9M |
| Net income | $17.4M | $-13.6M |
| Gross margin | 64.3% | 7.2% |
| Net margin | 13.4% | −10.5% |
| Return on equity | 28.3% | −18.0% |
| Diluted EPS | $0.20 | −$2.28 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-21.2M | $2.3M |
| Equity | $76.5M | $68.4M |
| Net debt / equity | — | −0.33× |
| Current ratio | 4.86× | 2.06× |
| Revenue CAGR 5y | 16.9% | 1.8% |
| Profit CAGR 5y | — | — |
NAGE and NAII book revenue within 15% of each other, and NAII closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | NAGE | NAII |
|---|---|---|
| FY2024 | $99.6M | $129.9M |
| FY2023 | $83.6M | $113.8M |
| FY2022 | $72.0M | $154.0M |
| FY2021 | $67.4M | $171.0M |
| FY2020 | $59.3M | $178.5M |
| FY2019 | $46.3M | $118.9M |
| FY2018 | $31.6M | $138.3M |
| FY2017 | $21.2M | $132.4M |
| FY2016 | $21.7M | $121.9M |
| FY2015 | $17.9M | $114.2M |
Net income by year
Bottom line
| Fiscal year | NAGE | NAII |
|---|---|---|
| FY2024 | $8.6M | $-13.6M |
| FY2023 | $-4.9M | $-7.2M |
| FY2022 | $-16.5M | $2.5M |
| FY2021 | $-27.1M | $10.7M |
| FY2020 | $-19.9M | $10.8M |
| FY2019 | $-32.1M | $-1.6M |
| FY2018 | $-33.3M | $6.5M |
| FY2017 | $-11.4M | $5.1M |
| FY2016 | $-2.9M | $7.2M |
| FY2015 | $-2.8M | $9.5M |
Advertisement
AdSense · Rectangle 336×280
More in this industry
Other pairs
The companies